|
Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study. |
|
|
Consulting or Advisory Role - GenomeDx; Genomic Health |
Speakers' Bureau - Genomic Health |
|
|
|
Stock and Other Ownership Interests - GRAIL; Thermo Fisher Scientific |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
|
Stock and Other Ownership Interests - GRAIL; Illumina |
|
|
|
Stock and Other Ownership Interests - GRAIL; Illumina |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - GRAIL |
|
|
Employment - GRAIL; Myriad Genetics |
Stock and Other Ownership Interests - GRAIL; Myriad Genetics |
|
|
Employment - McKesson; Texas Oncology (I) |
Leadership - Nemucore Medical Innovations; US Oncology |
Stock and Other Ownership Interests - McKesson; Nemucore Medical Innovations |
Honoraria - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; McKesson |
|
|
Research Funding - Eisai (Inst); GRAIL (Inst); Janssen Diagnostics (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Agena Bioscience; Celgene; Cynvenio Biosystems; GRAIL; Menarini Silicon Biosystems; Merck |